BA
ENZY

BlackRock Advisors’s Enzymotec Ltd ENZY Stock Holding History

BlackRock Advisors’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-208,806
Closed -$2.83M – 3754
2014
Q2 		$2.83M Hold
208,806
– – ﹤0.01% 1084
2014
Q1 		$4.6M Hold
208,806
– – ﹤0.01% 990
2013
Q4 		$5.64M Buy
+208,806
New +$4.97M 0.01% 957

Other funds holding ENZY

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MACM
March Altus Capital Management Greenwich, Connecticut $16M AUM 18.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

BlackRock Advisors's ENZY Position: Q3 2014 in Review

BlackRock Advisors sold out of Enzymotec Ltd (ENZY) in Q3 2014, closing a stake of 208,806 shares — an estimated $2.83M sold.

BlackRock Advisors first reported a position in ENZY in Q4 2013 and held it in 3 quarters. The position peaked at $5.64M in Q4 2013. 22 funds tracked by Wall St. Rank hold ENZY as of Q3 2014.

  • BlackRock Advisors reported no remaining Enzymotec Ltd position as of Q3 2014 after selling out during the quarter.
  • BlackRock Advisors sold 208,806 Enzymotec Ltd shares in Q3 2014, an estimated $2.83M.
  • BlackRock Advisors first reported a position in Enzymotec Ltd in Q4 2013 and held it in 3 quarters.
  • BlackRock Advisors's Enzymotec Ltd position peaked at $5.64M in Q4 2013.
  • 22 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q3 2014.

Based on BlackRock Advisors's 13F filing for Q3 2014, filed 29 Oct 2014.